Influence of osteogenic stimulation and VEGF treatment on in vivo bone formation in hMSC-seeded cancellous bone scaffolds by unknown
Lenze et al. BMC Musculoskeletal Disorders 2014, 15:350
http://www.biomedcentral.com/1471-2474/15/350RESEARCH ARTICLE Open AccessInfluence of osteogenic stimulation and VEGF
treatment on in vivo bone formation in
hMSC-seeded cancellous bone scaffolds
Ulrich Lenze1,2†, Florian Pohlig1,2,3†, Sebastian Seitz4, Christina Ern1,5, Stefan Milz6, Denitsa Docheva1*
and Matthias Schieker1Abstract
Background: Tissue engineering approaches for reconstruction of large bone defects are still technically immature,
especially in regard to sufficient blood supply. Therefore, the aim of the present study was to investigate the
influence of osteogenic stimulation and treatment with VEGF on new bone formation and neovascularization in
hMSC-loaded cancellous bone scaffolds in vivo.
Methods: Cubic scaffolds were seeded with hMSC and either cultured in stem cell medium or osteogenic
stimulation medium. One osteogenically stimulated group was additionally treated with 0.8 μg VEGF prior to
subcutaneous implantation in athymic mice. After 2 and 12 weeks in vivo, constructs and selected organs were
harvested for histological and molecular analysis.
Results: Histological analysis revealed similar vascularization of the constructs with and without VEGF treatment
and absence of new bone formation in any group. Human DNA was detected in all inoculated scaffolds, but a
significant decrease in cells was observed after 2 weeks with no further decrease after 12 weeks in vivo.
Conclusion: Under the chosen conditions, osteogenic stimulation and treatment with VEGF does not have any
influence on the new bone formation and neovascularization in hMSC-seeded cancellous bone scaffolds.
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Large bone defects caused by trauma, tumor or infection
still represent a major problem in reconstructive surgery.
Tissue engineering approaches for reconstruction of such
bone defects are appealing, but to date technically insuffi-
cient. In this context, one major problem – the blood sup-
ply during the first days in vivo – remains unsolved. Since
the rate of vessel ingrowth into a cell-loaded scaffold is hy-
pothesized to be less than one millimeter per day, a con-
siderable period is needed to provide sufficient blood
supply and delivery of substrates such as glucose and oxy-
gen to inner parts of the engineered scaffold [1,2]. Like-
wise, removal of waste products such as carbon dioxide* Correspondence: denitsa.docheva@med.uni-muenchen.de
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unless otherwise stated.and lactate via the bloodstream is delayed until a mature
vascular system is established. Since bone represents a
metabolically active tissue, the insufficient blood supply
during the first days in vivo might compromise cell sur-
vival and hence lead to failure of the graft integration [2].
Therefore, various tissue engineering strategies have been
developed to address this problem.
One promising approach is the use of growth factors
such as vascular endothelial growth factor (VEGF), which
plays an important role in inducing neovascularization and
bone healing [3]. Kaigler et al. reported on significantly in-
creased vascular perfusion and bone formation in irradiated
osseous defects using VEGF-releasing polymer scaffolds [4].
Beside the improved blood supply, this phenomenon could
also be ascribed to the VEGF-triggered bilateral communi-
cation between endothelial and osteogenic cell lineages
leading to a broad proliferation of endothelial cells andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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blasts [5,6].
The ability of hMSCs for differentiation along several cell
lineages is well known and depends on the tissue source,
whereas a substantial loss of their multi-potent properties
was observed during culture in vitro [7]. Although many
preclinical animal models showed ectopic as well as orthoto-
pic bone formation following implantation of 3D cell-loaded
constructs, questions regarding the optimal osteogenic dif-
ferentiation method for hMSCs as well as an effective initi-
ation of osteogenesis in vivo have not been finally clarified.
Therefore, the aim of this study was to determine if
VEGF treatment of osteogenically stimulated hMSCs
loaded on cancellous bone scaffolds is capable of enhan-
cing neovascularization and bone formation in an ec-
topic mouse model.
Methods
Scaffold loading and cultivation of human mesenchymal
stem cells
Human mesenchymal stem cells (hMSC) (Cambrex,
East Rutherford, USA), which were harvested and puri-
fied from bone marrow aspirates of one healthy donor
were purchased (Lonza, Basel, Switzerland) and culti-
vated in mesenchymal stem cell growth medium
(MSCGM) (Lonza, Basel, Switzerland). Fresh medium
was supplied three times per week. When cell layers
neared confluence, cells were detached using trypsin-
EDTA. Cultures were maintained in a humidified at-
mosphere of 95% air with 5% CO2 at 37°C.
The day before loading, cubic solvent-preserved and irra-
diated bovine cancellous bone scaffolds (Tutobone, Tutogen
Medical, Neunkirchen am Brand, Germany) with an edge
length of 3 mm were preincubated for 24 hours in MSCGM
[8]. A suspension of 1.1 × 106 hMSCs (passage 4) in 660 μl
medium was evenly applied to each scaffold. For maximum
seeding efficiency, scaffolds were turned and the cell suspen-
sion was resuspended onto each construct every 20 minutes.
After 6 hours, all scaffolds were transferred to well-plates for
further incubation. The seeding efficiency was assessed by
measuring the number of remaining cells within the super-
natant suspension in each well.
Following seeding, the scaffolds were cultured for
14 days either in MSCGM or in case of osteogenic stimu-
lation in Dulbecco’s Modified Eagle Medium (DMEM,
Gibco, Invitrogen, Carlsbad, USA) containing 10% fetal
bovine serum (FBS, Sigma-Aldrich, St. Louis, USA),
4 mM L-Glutamine, 100 nM Dexamethasone, 10 mM
b-Glycerophosphate and 50 mM L-Ascorbic acid 2-
phosphate. Medium was changed every second day
throughout the entire culture period. Directly before sub-
cutaneous implantation, 6 osteogenically stimulated cell-
loaded scaffolds were additionally injected with 0.8 μg
human VEGF (Peprotech, Rocky Hill, USA).Experimental design and surgical procedure
In total 12 athymic nude mice ranging from six to eight
weeks of age (nu/nu, Harlan Winkelmann, Rossdorf,
Germany) with a live weight of 25-30 g were used for
this study. Following intramuscular anaesthesia using a
fentanyl-medetomidin-midazolam mixture (0,625 mg
fetanyl, 0,125 mg medetomidin and 6,25 mg midazolam
per kilogramm body weight), two subcutaneous paraver-
tebral pouches were prepared by a blunt dissection.
Within the first experimental setup, unstimulated empty
scaffolds (n = 6, group 1) were implanted left paraverte-
brally, whereas scaffolds seeded with hMSCs (n = 6,
group 2) were implanted on the right side. Scaffolds
seeded with osteogenically stimulated hMSCs (n = 6,
group 3) as well as an additional VEGF treatment (n = 6,
group 4) were implanted in a second series paraverte-
brally to the right and left, respectively (Figure 1a). After
implantation, pouches were sutured in order to prevent
contact between implanted constructs.
After 2 and 12 weeks, scaffolds were harvested including
the surrounding tissue. One scaffold of each group was split
into two parts; one half destined for decalcification was
fixed in 100% methanol, while the other was put into a for-
maldehyde/methanol solution (formaldehyde 35%, metha-
nol 100%, isotonic glucose 1% and phosphate buffer), both
for 48 h (Figure 1b). The other scaffold of each group was
shock frozen in fluid nitrogen and stored at −80°C until
used for molecular analysis (Figure 1b). In addition, selected
organs (blood, brain, heart, lung, liver, kidneys, spleen, tes-
tes, scaffold surrounding skin and muscle tissue) were har-
vested, snap frozen in liquid nitrogen and stored at −80°C
until further use.
This study adhered to the ARRIVE guidelines, was ap-
proved by the “Government of Upper Bavaria” and all
animals were handled according to the LMU guidelines
(Ludwig-Maximilians-University of Munich) for the care
and use of laboratory animals.
Histological analysis
Scaffolds fixed in the formaldehyde/methanol solution were
dehydrated in a graded series of ethanol over 5 days and
afterwards embedded into methyl methacrylate (MMA).
Next, 4 μm thick sections were collected from each scaffold
by using a Polycut microtome (Reichert-Jung, Heidelberg,
Germany). Sections were stained with Goldner’s Trichrome
and Toluidine Blue.
Scaffolds fixed in methanol were decalcified with 5%
EDTA/PBS solution over 4 weeks. The solution was chan-
ged every third day. Sections of 12 μm thickness were ob-
tained by using a cryomicrotome (Microm, Walldorf,
Germany) and then stained with Hematoxylin and Eosine.
All sections were investigated using a light micro-
scope (Axioskop, Zeiss, Jena, Germany) and graded by 3
independent observers for the presence and extent of: i)
Figure 1 Experimental setup. In total 12 athymic nude mice ranging from six to eight weeks of age were used for this study (a). According to
the seeding and culture conditions, 4 groups were built: 1. blank scaffolds, 2. seeded with hMSCs, 3. seeded with osteogenically stimulated
hMSCs, 4. seeded with osteogenically stimulated hMSCs and treated with VEGF. After 2 and 12 weeks, scaffolds were harvested including the
surrounding tissue. One scaffold of each group was split into two parts (b): one half was destined for decalcification the other for un-decalcified
histological examination. The other scaffold of each group was shock frozen in fluid nitrogen and stored at −80°C until use for molecular
analysis (b).
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larization and v) foreign body giant cells. The grading
scale ranged from 1 (tissue extent 1-20% of the scaffold/
single cells in the border areas) to 5 (tissue extent 80-
100%/lots of cells in all areas) according to the established
method by van Gaalen [9].
Extraction of genomic DNA
The isolation of DNA from the scaffolds was performed
with DNeasy blood and tissue kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions. In
brief, harvested tissue samples were lysed with proteinase
K (>600 mAU/ml). The DNA in the lysed samples was
then absorbed on a silica matrix and cell debris was re-
moved by washing with DNeasy washing buffer. Finally,
the DNA was collected by elution in AE buffer (Qiagen,
Hilden, Germany) and photometrically quantified.
Semiquantitative polymerase chain reaction (PCR)
Detection of human DNA within the scaffolds and various
organs was performed by genomic PCR. An 850 bp frag-
ment of the α-satellite region of the human chromosome
17 was amplified using primers as previously described in
Becker et al. [10].
Each PCR reaction (end volume of 50 μl) contained
250 ng of human genomic DNA, 200 μM of nucleotide
mixture, 250 μM of each primer, 2.5 U Taq Polymerase and
Q-solution (Qiagen, Hilden, Germany) supplemented with
15 nM MgCl2.
An initial denaturation of 3 min. at 94°C was followed by
40 cycles comprised of 30 sec. at 94°C, annealing at 58°C
for 1 min. and for another 1 min. a polymerase reaction at72°C. Finally, 10 minutes of polymerisation and an inter-
ruption of the reaction by cooling down to 4°C completed
the cycles. Amplified DNA fragments (850 bp) were trans-
ferred onto 1.75% agarose gels and after the electrophoresis,
they were stained with ethidium bromide and analysed
using ultraviolet light.
Isolated DNA from hMSCs served as positive control
while DNA extracted from murine fibroblasts served as
negative control in each PCR run. To prove the PCR sensi-
tivity, genomic DNA mixture containing DNA from mur-
ine fibroblasts and hMSCs in different ratios (1 × 106
murine fibroblasts + 10 hMSCs and 1 × 106 mouse fibro-
blasts + 1 hMSC) was also used in each PCR run.
Quantitative PCR
Quantitative PCR was performed by using LightCycler
technology (Roche, Mannheim, Germany). A specific
human primer set was purchased from Search-LC
(Search-LC, Heidelberg, Germany). The final volume of
each PCR-reaction was 20 μl containing 10 μl of 5 ng
genomic DNA, 10 μl of a PCR-Mix (6 μl PCR grade
water, 2 μl of primers and 2 μl of LightCycler Fast Start
Master SYBR Green I; Roche).
Each PCR cycle consisted of a 10 second denaturation at
95°C followed by annealing at 68°C for 10 sec. with a transi-
tion to 58°C in steps of 0.5°C per cycle. Elongation was per-
formed at 72°C for 16 seconds during which fluorescence
intensity was measured in each cycle. The temperature tran-
sition rate of all steps was 20°C per second. Serial dilution
steps of human genomic DNA in 10 μl distilled water
(60 ng, 6 ng, 0.6 ng, 0.06 ng, 0.006 ng, 0.0006 ng DNA) were
used to generate standard curves. In every PCR, DNA
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from murine fibroblasts served as a negative control.
Finally, the number of cells on the scaffold after explant-
ation was calculated by the measured amount of human
DNA and the common presumption of a genomic DNA
content of 6 pg in eukaryotic cells.
Statistical analysis
Comparison analysis was performed with the quantita-
tive PCR data using SPSS software (IBM, Armonk, USA)
and the unpaired t-test. The results are shown as mean




From the original amount of 1.1 × 106 hMSCs applied onto
the scaffolds, a mean of 7.1 × 105 cells (median 7.0 × 105
cells, range 4.1 × 105 – 9.1 × 105 cells) adhered to the scaf-
fold (Figure 2). The mean seeding efficiency of all scaffolds
was 64.8% (median 64.1%, range 41.7% – 83.3%). The statis-
tical evaluation of seeding efficiencies did not show signifi-
cant differences between the four experimental groups.
Animal experiments
All animals showed good general conditions, dry wounds
with no sign of irritation as well as appropriate behavior at
the time of explantation. No animals died or suffered
from diseases during the whole study duration prior to
euthanasia.
Histological findings
After an implantation period of 2 weeks, an incipient in-
growth of fibrous- and granulation tissue as well as small
vessels was observed in each scaffold. In all groups (1.
unstimulated empty scaffolds, 2. inoculated with hMSCs,
3. inoculated with osteogenic stimulated hMSCs, 4. inoc-
ulated with osteogenically stimulated hMSCs and treatedFigure 2 Cell count after scaffold seeding with hMSCs. From the
original amount of 1.1 × 106 hMSCs, a mean of 7.1 × 105 cells adhered
to the scaffold. Group 1: blank scaffolds (control); Group 2: seeded with
hMSCs; Group 3: seeded with osteogenically stimulated hMSCs; Group 4:
seeded with osteogenically stimulated hMSCs and treated with VEGF.with VEGF), newly formed capillaries and small vessels
were detected, lying evenly distributed mainly in the
outer regions of the scaffold (Figure 3). Granulation tis-
sue was also observed in all groups (Figure 4). Inner
parts of the constructs contained scattered fat cells, in-
flammatory cells, and sometimes necrotic areas. Multi-
nucleated giant cells were found in scaffolds from all
groups. These cells were mostly aligned in groups of 2–4
along the edge of the scaffolds. Fat cells were observed
within loose fibrous tissue, especially in outlying areas
covering more than 20% of the scaffold surface. No ap-
parent differences in the occurrence and distribution of
necrotic areas were detected. Newly formed osteoid,
bone- or cartilage tissue was not apparent after an im-
plantation period of 2 weeks.
In the 12 weeks group, further ingrowth of the surround-
ing tissue into the constructs occurred. Especially, a change
in the vascularization and the appearance of bigger fat cell
aggregations was noticeable in all scaffolds (Figure 5). Com-
pared to the histological results after 2 weeks of implant-
ation, a clear increase in size and amount of vessels was
detected after 12 weeks in all groups. Capillaries, venules
and arterioles were evenly distributed over all parts of the
scaffolds. Furthermore, an increased expansion of fat cells
was found in all groups, covering up to 60% of the scaffold
surface in some cases (Figure 6). The highest extent of fatty
tissue was observed in unstimulated empty (group 1) and
inoculated scaffolds (group 2), while the lowest extent was
found in osteogenically stimulated constructs (group 3).
Next to the fatty tissue, flanking necrotic areas were de-
tected. Multinucleated giant cells showed an inhomogen-
eous distribution pattern and were found in the scaffold
periphery but also in central areas. After an implantation
period of 12 weeks, neither newly formed osteoid nor bone
or cartilage tissue was obtained.
No differences regarding vascularization or tissue reaction
and formation were observed between the groups independ-
ent from the different culture and stimulation conditions.
Semi-quantitative PCR
Human DNA was found in all inoculated scaffolds after ex-
plantation at both points in time. In blank scaffolds, no hu-
man DNA was detected. Moreover, we did not detect
human DNA in any of the explanted organs as well as in
the soft tissue surrounding the implanted scaffolds. Cell sus-
pensions with hMSCs and murine cells served as controls
allowing a detection of even 1 hMSC in 106 murine cells.
Quantitative PCR
With real time PCR, a significant decrease (p <0.001) of
human DNA and accordingly the directly proportional
cell numbers on all cell-seeded constructs (2 and 12 weeks
in vivo) could be measured compared to the amount of
initially seeded cells (Figure 7). After 12 weeks, a further
Figure 3 Vascularization after 2 weeks. Capillaries and small vessels (thin arrows) were detected in all groups after 2 weeks of in vivo implantation.
In addition, multinucleated giant cells were observed on the scaffold surface (thick arrows). [Gp = Group, os-hMSCs = osteogenically stimulated hMSCs]
Goldner’s trichrome: scale bars: 50 μms.
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ulated with osteogenically stimulated hMSCs and VEGF
treatment). Only for group 3 (seeded with osteogenically
stimulated hMSCs), a slight increase of the cell number
was observed after 12 weeks compared to 2 weeks
(Figure 8). We identified higher cell numbers in the scaf-
folds with additional VEGF (group 4) after 2 weeks in
comparison to just osteogenically stimulated scaffolds
(group 3). After an implantation time of 12 weeks, group
4 showed inferior cell numbers. However, the above-
mentioned differences were statistically not significant.
Discussion
In this study, we aimed to evaluate the influence of osteo-
genic stimulation and application of vascular endothelial
growth factor (VEGF) on bone formation in hMSC-seeded
cancellous bone scaffolds after 2 and 12 weeks of subcuta-
neous implantation. During the implantation period, an in-
growth of surrounding host tissue was observed in all
groups. Migration of human cells to host organs after xeno-
genic implantation was not seen in any of the animals, thus
confirming previous results of our group [8]. Human DNA
was detected in explanted scaffolds at all points in time, but
a significant decrease in cells within the scaffolds could bemeasured in vivo compared to the amount of initially
seeded cells. Neither bone formation nor higher amounts
of neovascularization was observed. According to the jour-
nal guidelines ARRIVE check list for this study has been
provided as Additional file 1.
hMSC cultivation
The high amount of mesenchymal stem cells (hMSCs)
within the commercially available cells used in this study
was proven and described previously [11]. However, au-
thors reporting on successful in vivo regeneration of
bone often used BMSCs (Bone Marrow Stroma Cells)
gained from bone marrow containing quantitatively
more pre-differentiated progenitor cells than hMSCs
[12,13]. The presence of such progenitor cells, which
can be expanded in vitro by osteogenic stimulation, is
crucial for ectopic bone formation [14,15]. In this con-
text, additional contribution of BMP-2 and FGF-2
should be taken into account since an increased osteo-
blastic differentiation in vitro might have positive effects
on ectopic bone formation in vivo [16].
The lack of newly formed bone could also be attributed
to the static cultivation procedure. Since an ideal nutrient
supply plays a major role during the initiation and
Figure 4 Tissue after 2 weeks. Granulation tissue (*) was observed in all groups after 2 weeks in vivo. [Gp = Group, os-hMSCs = osteogenically
stimulated hMSCs] Hematoxylin-Eosin: scale bars: 200 μms.
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dynamic cultivation could be beneficial. Dynamic com-
pared to static cultivation of osteogenically stimulated
cell matrix constructs was shown to enhance the forma-
tion of an extracellular matrix in vitro which facilitates
more new bone formation in vivo [17]. Additionally, the
differentiation of osteogenically stimulated cells along
the osteoblastic cascade is positively influenced by cyto-
mechanical forces actuated within dynamic culture
tanks [18]. In this context, various methods to stimulate
cells with mechanical forces were reported including
tensile stress, compressive stress, shear stress, vibration
and magnetic stimuli [19].
A decrease of oxygen concentration towards the cen-
ter of the scaffold was shown under static cultivation,
whereas the oxygen concentration of dynamically cul-
tured constructs did not fall below 4% after 5 days [20].
These data reinforce the assumption that a considerable
number of cells probably died during static cultivation
in vitro due to a decreasing oxygen gradient towards the
inner parts of the construct. This could be one reason
for our results which show a significant decrease of cell
numbers after 2 weeks in vivo but no further significant
decrease after 12 weeks.Vasculature
Taking into consideration that capillaries were predom-
inantly located in the outer scaffold areas after 2 weeks
in vivo, a further reason for the considerable decrease of
hMSCs might be the lack of a sufficient vascular supply
[8]. In our opinion, physical prerequisites regarding the
diffusion threshold of 200 μm - 3.5 mm were met by the
use of small cubic scaffolds with an edge length of 3 mm
[21,22]. However, considering the obtained results, cell
death must be assumed at least for inner cell layers
within the scaffold. Likewise, Potier et al. reported on
broad cell death in vitro after a maximum of 5 days
when the cells were exposed to hypoxia and deprivation
of serum [23]. In contrast, maintaining constant or pre-
conditioning levels of hypoxia was shown to improve
the osteogenic potential of hMSCs and possibly preserve
the stem cell character of hMSCs in vitro [24]. The fact
that even in the VEGF group sufficient vascular supply
was not initiated and cell survival was not achieved
could be attributed to the biological instability of VEGF
in vivo as well as the short stimulation time [3]. This
shortcoming could be overcome by the use of novel scaf-
folds binding VEGF by heparin crosslinking and thus,
achieving localized and sustained delivery of this growth
Figure 5 Vascularization after 12 weeks. After 12 weeks, further ingrowth of the surrounding tissue into the constructs occurred. Especially, a change in
the vascularization (arrows) and the appearance of bigger fat cell aggregations (*) was noticed in all scaffolds. [Gp =Group, os-hMSCs = osteogenically
stimulated hMSCs] Goldner’s trichrome: scale bars: 200 μms.
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cutaneous implantation of heparinized scaffolds loaded
with VEGF was observed [3]. Further improvements could
be achieved by developing prevascularized cell-matrix-
constructs providing a sufficient nutrient supply at early
stages after implantation [26]. Prevascularized constructs,
allowing an early functioning metabolic cycle, were shown
to improve the survival rate of osteoblasts in vivo com-
pared to non-prevascularized constructs [27].
Tissue
The initiation of inflammatory processes by implantation of
biological or synthetic materials is evident [8,28,29]. Essen-
tial parameters for the character and value of biological re-
action are material properties and quality of the implanted
foreign body [30]. Therefore, surface enlargement by means
of interconnecting pores could be responsible for an
increased invasion of reactive cells leading to foreign body
reactions even in immunodeficient, athymic mice [31]. This
might affect the survival of cells as a decrease of pH and re-
lease of degradation enzymes lead to changes in homoeo-
stasis [30]. If and to which extent phagocytosis of human
mesenchymal stem cells could take place in the course of
such foreign body reactions remains unclear [32,33].Development of granulation tissue was observable in
all groups after 2 weeks in vivo. We suggest that this
phenomenon is to be explained by the physiological tis-
sue chronology during foreign body reactions [30]. The
production of e.g. TNFα or EGF by macrophages is re-
sponsible for the initiation of neovascularization and
proliferation of fibroblasts resulting in the formation of
granulation tissue, which is replaced by permanent tissue
afterwards. Consistent with previous results, a regression
of granulation tissue was observed after 12 weeks in all
groups [8].
No bone formation was observed in any of the scaffolds
indicating an insufficient amount of osteoprogenitor cells
as well as vascular supply. Low osteogenic capacity of the
ectopic implantation site as well as missing osteoinductive
properties of the scaffold must be assumed as possible
reasons for our results [15]. Therefore, implantation of the
scaffolds in orthotopic sites might improve bone forma-
tion by chemotactic agents. However, Kruyt et al. have
already demonstrated no significant difference in cell-
based bone formation between ectopic and orthotopic im-
plantation [34].
The study is limited, beside the abovementioned short-
comings, especially by a small sample size. Therefore,
Figure 6 Tissue after 12 weeks. An increased expansion of fat cells (*) covering up to 60% of the scaffold surface and vessels (thin arrows) was
found in all groups after 12 weeks in vivo implantation. Next to the fatty tissue, necrotic areas (°) were detectable in all groups. Pictures on the
right side show the inserts in the left pictures. [Gp = Group, os-hMSCs = osteogenically stimulated hMSCs] Toluidine blue: scale bars: 200 μms (left),
50 μms (right).
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stimulating murine cells. Alternatively, the use of co-
cultures such as osteoblasts and endothelial cells could
help to induce a sufficient blood supply in vivo and hence
the new formation of bone.Figure 7 Cells on the scaffold. The number of cells on the
scaffolds after explantation compared to the amount of initially
seeded cells decreased in all groups.Conclusion
Under the chosen prerequisites, VEGF treatment of
osteogenically stimulated hMSCs loaded on cancellous
bone scaffolds is not sufficient to enhance neovasculari-
zation, bone formation and/or improved cell survival.
Human DNA can be found in inoculated scaffolds evenFigure 8 Increase of cells in group 3. Number of cells on the
scaffolds after 2 and 12 weeks in vivo in group 3 (seeded with
osteogenically stimulated hMSCs) and group 4 (seeded with
osteogenically stimulated hMSCs and treated with VEGF).
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surrounding following xenotransplantation.
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Abbrevations
VEGF: Vascular Endothelial Growth Factor; hMSC: human Mesenchymal Stem
Cells; EDTA: Ethylenediaminetetraacetic acid; CO2: Carbon dioxide;
MSCGM: Mesenchymal Stem Cells Growth Medium; DMEM: Dubecco`s
Modified Eagle Medium; FBS: Fetal Bovine Serum; MMA: Methyl Methacrylate;
PBS: Phosphate Buffered Saline; DNA: Deoxyribonucleic acid; PCR: Polymerase
Chain Reaction; SPSS: Statistical Package for the Social Sciences; BMSCs: Bone
Marrow Stroma Cells; BMP-2: Bone Morphogenetic Protein-2;
FGF-2: Fibroblast Growth Factor-2; pH: potential of hydrogen; TNFα: Tumor
Necrosis Factor α; EGF: Epidermal Growth Factor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
UL and FP were in charge of data acquisition, drafting and writing the
manuscript and contributed to the conception of the study. SS, CE, SM and
DD participated in the conception and design of the study, helped to draft
the manuscript and gave substantive intellectual feedback on the
manuscript. DD and MS contributed to the conception and the design of
the study, the interpretation of data and gave intellectual feedback on the
manuscript. All authors read and approved the final manuscript.
Acknowledgement
This work was supported by grants of the Bavarian Research Foundation
(Collaboration for Tissue Engineering and Rapid Prototyping). We gratefully
acknowledge Tutogen for providing the scaffolds (Tutobone) as well as
Brigitte Hackl and Claudia Harbauer for their excellent technical assistance.
This work contains data from the theses of UL and FP and is published with
permission of the medical faculty of the LMU Munich. Furthermore, we
thank Fritz Seidl, MA Interpreting and Translating, for his excellent language
copyediting. The current address of Prof. Dr. Matthias Schieker is at Amgen
GmbH, Munich, Germany.
Author details
1Laboratory of Experimental Surgery and Regenerative Medicine, Department
of Surgery, University of Munich (LMU), Munich, Germany. 2Department of
Orthopedics and Orthopedic Sports Medicine, Technical University of Munich
(TU), Munich, Germany. 3Department of Trauma Surgery, Technical University
of Munich (TU), Munich, Germany. 4Department of Orthopaedics, University
Medical Center Hamburg-Eppendorf, Hamburg, Germany. 5Department of
Restorative Dentistry & Periodontology, University of Munich (LMU), Munich,
Germany. 6Department of Anatomy, University of Munich (LMU), Munich,
Germany.
Received: 10 February 2014 Accepted: 23 September 2014
Published: 16 October 2014
References
1. Mikos AG, Sarakinos G, Lyman MD, Ingber DE, Vacanti JP, Langer R:
Prevascularization of porous biodegradable polymers. Biotechnol Bioeng
1993, 42:716–723.
2. Santos MI, Reis RL: Vascularization in bone tissue engineering: physiology,
current strategies, major hurdles and future challenges. Macromol Biosci
2010, 10:12–27.
3. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors.
Nat Med 2003, 9:669–676.
4. Kaigler D, Wang Z, Horger K, Mooney DJ, Krebsbach PH: VEGF scaffolds
enhance angiogenesis and bone regeneration in irradiated osseous
defects. J Bone Miner Res 2006, 21:735–744.
5. Clarkin CE, Emery RJ, Pitsillides AA, Wheeler-Jones CP: Evaluation of VEGF-
mediated signaling in primary human cells reveals a paracrine action forVEGF in osteoblast-mediated crosstalk to endothelial cells. J Cell Physiol
2008, 214:537–544.
6. Grellier M, Granja PL, Fricain JC, Bidarra SJ, Renard M, Bareille R, Bourget C,
Amedee J, Barbosa MA: The effect of the co-immobilization of human
osteoprogenitors and endothelial cells within alginate microspheres on
mineralization in a bone defect. Biomaterials 2009, 30:3271–3278.
7. Via AG, Frizziero A, Oliva F: Biological properties of mesenchymal Stem
Cells from different sources. Muscles Ligaments Tendons J 2012, 2:154–162.
8. Seitz S, Ern K, Lamper G, Docheva D, Drosse I, Milz S, Mutschler W, Schieker M:
Influence of in vitro cultivation on the integration of cell-matrix constructs
after subcutaneous implantation. Tissue Eng 2007, 13:1059–1067.
9. van Gaalen SM, Dhert WJ, van den Muysenberg A, Oner FC, Van Blitterswijk
C, Verbout AJ, De Bruijn JD: Bone tissue engineering for spine fusion: an
experimental study on ectopic and orthotopic implants in rats. Tissue Eng
2004, 10:231–239.
10. Becker M, Nitsche A, Neumann C, Aumann J, Junghahn I, Fichtner I:
Sensitive PCR method for the detection and real-time quantification of
human cells in xenotransplantation systems. Br J Cancer 2002,
87:1328–1335.
11. Docheva D, Popov C, Mutschler W, Schieker M: Human mesenchymal stem
cells in contact with their environment: surface characteristics and the
integrin system. J Cell Mol Med 2007, 11:21–38.
12. Mauney JR, Jaquiery C, Volloch V, Heberer M, Martin I, Kaplan DL: In vitro
and in vivo evaluation of differentially demineralized cancellous bone
scaffolds combined with human bone marrow stromal cells for tissue
engineering. Biomaterials 2005, 26:3173–3185.
13. Bareille R, Lafage-Proust MH, Faucheux C, Laroche N, Wenz R, Dard M,
Amedee J: Various evaluation techniques of newly formed bone in
porous hydroxyapatite loaded with human bone marrow cells implanted
in an extra-osseous site. Biomaterials 2000, 21:1345–1352.
14. Matsushima A, Kotobuki N, Tadokoro M, Kawate K, Yajima H, Takakura Y,
Ohgushi H: In vivo osteogenic capability of human mesenchymal cells
cultured on hydroxyapatite and on beta-tricalcium phosphate.
Artif Organs 2009, 33:474–481.
15. Kruyt MC, de Bruijn JD, Wilson CE, Oner FC, van Blitterswijk CA, Verbout AJ,
Dhert WJ: Viable osteogenic cells are obligatory for tissue-engineered
ectopic bone formation in goats. Tissue Eng 2003, 9:327–336.
16. Maegawa N, Kawamura K, Hirose M, Yajima H, Takakura Y, Ohgushi H:
Enhancement of osteoblastic differentiation of mesenchymal stromal
cells cultured by selective combination of bone morphogenetic protein-
2 (BMP-2) and fibroblast growth factor-2 (FGF-2). J Tissue Eng Regen Med
2007, 1:306–313.
17. Wang Y, Uemura T, Dong J, Kojima H, Tanaka J, Tateishi T: Application of
perfusion culture system improves in vitro and in vivo osteogenesis of
bone marrow-derived osteoblastic cells in porous ceramic materials.
Tissue Eng 2003, 9:1205–1214.
18. Zilkens C, Logters T, Bittersohl B, Krauspe R, Lensing-Hohn S, Jager M:
Spinning around or stagnation - what do osteoblasts and chondroblasts
really like? Eur J Med Res 2010, 15:35–43.
19. Delaine-Smith RM, Reilly GC: Mesenchymal stem cell responses to
mechanical stimuli. Muscles Ligaments Tendons J 2012, 2:169–180.
20. Volkmer E, Drosse I, Otto S, Stangelmayer A, Stengele M, Kallukalam BC,
Mutschler W, Schieker M: Hypoxia in static and dynamic 3D culture
systems for tissue engineering of bone. Tissue Eng Part A 2008,
14:1331–1340.
21. Rouwkema J, Rivron NC, van Blitterswijk CA: Vascularization in tissue
engineering. Trends Biotechnol 2008, 26:434–441.
22. Kruyt MC, Dhert WJ, Yuan H, Wilson CE, van Blitterswijk CA, Verbout AJ, de
Bruijn JD: Bone tissue engineering in a critical size defect compared to
ectopic implantations in the goat. J Orthop Res 2004, 22:544–551.
23. Potier E, Ferreira E, Meunier A, Sedel L, Logeart-Avramoglou D, Petite H: Prolonged
hypoxia concomitant with serum deprivation induces massive human
mesenchymal stem cell death. Tissue Eng 2007, 13:1325–1331.
24. Volkmer E, Kallukalam BC, Maertz J, Otto S, Drosse I, Polzer H, Bocker W,
Stengele M, Docheva D, Mutschler W, Schieker M: Hypoxic preconditioning of
human mesenchymal stem cells overcomes hypoxia-induced inhibition of
osteogenic differentiation. Tissue Eng Part A 2010, 16:153–164.
25. Chen L, He Z, Chen B, Yang M, Zhao Y, Sun W, Xiao Z, Zhang J, Dai J:
Loading of VEGF to the heparin cross-linked demineralized bone matrix
improves vascularization of the scaffold. J Mater Sci Mater Med 2010,
21:309–317.
Lenze et al. BMC Musculoskeletal Disorders 2014, 15:350 Page 10 of 10
http://www.biomedcentral.com/1471-2474/15/35026. Steffens L, Wenger A, Stark GB, Finkenzeller G: In vivo engineering of a
human vasculature for bone tissue engineering applications. J Cell Mol
Med 2009, 13:3380–3386.
27. Arkudas A, Beier JP, Heidner K, Tjiawi J, Polykandriotis E, Srour S, Sturzl M,
Horch RE, Kneser U: Axial prevascularization of porous matrices using an
arteriovenous loop promotes survival and differentiation of transplanted
autologous osteoblasts. Tissue Eng 2007, 13:1549–1560.
28. Yanagida H, Okada M, Masuda M, Ueki M, Narama I, Kitao S, Koyama Y,
Furuzono T, Takakuda K: Cell adhesion and tissue response to
hydroxyapatite nanocrystal-coated poly(L-lactic acid) fabric. J Biosci
Bioeng 2009, 108:235–243.
29. Barbosa JN, Amaral IF, Aguas AP, Barbosa MA: Evaluation of the effect of
the degree of acetylation on the inflammatory response to 3D porous
chitosan scaffolds. J Biomed Mater Res A 2009, 93:20–28.
30. Anderson JM, Rodriguez A, Chang DT: Foreign body reaction to
biomaterials. Semin Immunol 2008, 20:86–100.
31. Rodriguez A, Macewan SR, Meyerson H, Kirk JT, Anderson JM: The foreign body
reaction in T-cell-deficient mice. J Biomed Mater Res A 2009, 90:106–113.
32. Xia Z, Ye H, Choong C, Ferguson DJ, Platt N, Cui Z, Triffitt JT: Macrophagic
response to human mesenchymal stem cell and poly(epsilon-
caprolactone) implantation in nonobese diabetic/severe combined
immunodeficient mice. J Biomed Mater Res A 2004, 71:538–548.
33. Cabilly S, Gallily R: Non-immunological recognition and killing of
xenogeneic cells by macrophages. II. Mechanism of killing.
Immunology 1981, 44:357–365.
34. Kruyt MC, Dhert WJ, Oner FC, van Blitterswijk CA, Verbout AJ, de Bruijn JD: Analysis
of ectopic and orthotopic bone formation in cell-based tissue-engineered
constructs in goats. Biomaterials 2007, 28:1798–1805.
doi:10.1186/1471-2474-15-350
Cite this article as: Lenze et al.: Influence of osteogenic stimulation and
VEGF treatment on in vivo bone formation in hMSC-seeded cancellous
bone scaffolds. BMC Musculoskeletal Disorders 2014 15:350.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
